/
GNPX
$4.87+$0.14 (+2.96%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.4M
1M shares
52-week range
$4.00 – $1,210.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-115715.13
Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
www.genprex.com- Employees
- 13
- IPO / List date
- Mar 29, 2018
- HQ
- AUSTIN, TX
Held by traders on TradeandTell
No one on the platform currently holds GNPX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GNPX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-07-16 | 1-for-22reverse |
| 2025-10-21 | 1-for-50reverse |
| 2024-02-02 | 1-for-40reverse |
Recent trades on TradeandTell
No one on the platform has traded GNPX yet.
